Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Neoadjuvant Study of Letrozole in Combination With PD0332991 (Oral CDK 4/6 Inhibitor) for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

NCT01709370 is registered in ClinicalTrials.gov with Organisation for Oncology and Translational Research as lead sponsor.

NCT NCT01709370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01709370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Neoadjuvant Study of Letrozole in Combination With PD0332991 (Oral CDK 4/6 Inhibitor) for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women
Lead sponsor
Organisation for Oncology and Translational Research
Phase
Phase 2
Overall status
Unknown status
Start date
February 29, 2012
Completion date
Not reported
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

er positive, her2 negative breast cancer